Myriad Genetics to Present Five Studies at the 2019 American Society of Human Genetics Annual Meeting
October 08 2019 - 7:05AM
Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular
diagnostics and precision medicine, today announced that it will
present results from five studies at the 2019 American Society of
Human Genetics (ASHG) annual meeting being held Oct. 15–19, 2019 in
Houston, TX. Abstracts of the company's presentations are
available at:
https://www.ashg.org/2019meeting/pages/abstract_assignments.shtml
"We are excited to present multiple studies at this year’s ASHG
meeting," said James Goldberg, M.D., board certified maternal fetal
medicine specialist, medical geneticist and chief medical officer,
Myriad Women’s Health. “We continue our commitment to advancing the
science of genetic testing and delivering on the promise of
precision medicine.”
A list of presentations at 2019 ASHG are below. Follow
Myriad on Twitter via @myriadgenetics and keep up to date with ASHG
meeting news and updates by using the hashtag #ASHG19.
Featured Research at 2019 ASHG |
Myriad Product |
Abstract |
Author |
Poster Details |
myRisk® Hereditary Cancer
|
Common potential pathogenic variants in PMS2CL that can present in
PMS2 with extremely low frequencies |
Shujuan Pan |
Poster (2424W )Wednesday, Oct. 16, 20193:00-4:00 p.m.Exhibit Hall,
Level 1 |
Functional classification of selected exonic splicing variants
occurring outside of canonical 5’ and 3’ exon boundaries in
cancer-predisposing genes |
PaolaNix |
Poster (898T)Thursday, Oct. 17, 20193:00-4:00 p.m.Exhibit Hall,
Level 1 |
|
Foresight® Carrier Screen
|
Leveraging large datasets accumulated through population carrier
screening to inform variant classification |
DavidTran |
Poster (1575W)Wednesday, Oct. 16, 20192:00-3:00 p.m.Exhibit Hall,
Level 1 |
Accurate and high-resolution copy number variant detection in
clinical germline screening |
JianiLi |
Poster (1653W)Wednesday, Oct. 16, 20192:00-3:00 p.m.Exhibit Hall,
Level 1 |
A deep learning model for accurate variant calling in congenital
adrenal hyperplasia |
SunHong |
Poster (1410W)Wednesday, Oct. 16, 20193:00-4:00 p.m.Exhibit Hall,
Level 1 |
|
About Myriad myRisk® Hereditary
CancerThe Myriad myRisk Hereditary Cancer test uses an
extensive number of sophisticated technologies and proprietary
algorithms to evaluate 35 clinically significant genes associated
with eight hereditary cancer sites including: breast, colon,
ovarian, endometrial, pancreatic, prostate and gastric cancers and
melanoma.
About Foresight® Carrier
ScreenThe Myriad Foresight Carrier Screen is designed to
maximize detection of at-risk couples for serious, prevalent, and
clinically-actionable conditions. Foresight has a rigorous disease
selection that focuses on 175+ conditions that provides meaningful
information to patients. Additionally, Foresight offers superior
technology with unmatched detection rates for the vast majority of
genes on the panel (>99% across ethnicities) which means
patients can trust both positive and negative results.
About Myriad GeneticsMyriad Genetics Inc. is a
leading precision medicine company dedicated to being a trusted
advisor transforming patient lives worldwide with pioneering
molecular diagnostics. Myriad discovers and commercializes
molecular diagnostic tests that: determine the risk of developing
disease, accurately diagnose disease, assess the risk of disease
progression, and guide treatment decisions across six major medical
specialties where molecular diagnostics can significantly improve
patient care and lower healthcare costs. Myriad is focused on
five critical success factors: building upon a solid
hereditary cancer foundation, growing new product volume, expanding
reimbursement coverage for new products, increasing RNA kit revenue
internationally and improving profitability with Elevate
2020. For more information on how Myriad is making a
difference, please visit the Company's website: www.myriad.com.
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris
AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer,
myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx,
myChoice HRD, EndoPredict, Vectra, GeneSight, riskScore, Prolaris,
Foresight and Prequel are trademarks or registered trademarks of
Myriad Genetics, Inc. or its wholly owned subsidiaries in the
United States and foreign countries. MYGN-F, MYGN-G.
Safe Harbor StatementThis press release
contains "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995, including
statements relating to data being presented for its genetic tests
at the 2019 American Society of Human Genetics Meeting being held
Oct. 15–19, 2019 in Houston, TX; and the Company's strategic
directives under the caption "About Myriad Genetics." These
"forward-looking statements" are based on management's current
expectations of future events and are subject to a number of risks
and uncertainties that could cause actual results to differ
materially and adversely from those set forth in or implied by
forward-looking statements. These risks and uncertainties
include, but are not limited to: the risk that sales and profit
margins of our molecular diagnostic tests and pharmaceutical and
clinical services may decline; risks related to our ability to
transition from our existing product portfolio to our new tests,
including unexpected costs and delays; risks related to decisions
or changes in governmental or private insurers’ reimbursement
levels for our tests or our ability to obtain reimbursement for our
new tests at comparable levels to our existing tests; risks related
to increased competition and the development of new competing tests
and services; the risk that we may be unable to develop or achieve
commercial success for additional molecular diagnostic tests and
pharmaceutical and clinical services in a timely manner, or at all;
the risk that we may not successfully develop new markets for our
molecular diagnostic tests and pharmaceutical and clinical
services, including our ability to successfully generate revenue
outside the United States; the risk that licenses to the technology
underlying our molecular diagnostic tests and pharmaceutical and
clinical services and any future tests and services are terminated
or cannot be maintained on satisfactory terms; risks related to
delays or other problems with operating our laboratory testing
facilities and our healthcare clinic; risks related to public
concern over genetic testing in general or our tests in particular;
risks related to regulatory requirements or enforcement in the
United States and foreign countries and changes in the structure of
the healthcare system or healthcare payment systems; risks related
to our ability to obtain new corporate collaborations or licenses
and acquire new technologies or businesses on satisfactory terms,
if at all; risks related to our ability to successfully integrate
and derive benefits from any technologies or businesses that we
license or acquire; risks related to our projections about our
business, results of operations and financial condition; risks
related to the potential market opportunity for our products and
services; the risk that we or our licensors may be unable to
protect or that third parties will infringe the proprietary
technologies underlying our tests; the risk of patent-infringement
claims or challenges to the validity of our patents or other
intellectual property; risks related to changes in intellectual
property laws covering our molecular diagnostic tests and
pharmaceutical and clinical services and patents or enforcement in
the United States and foreign countries, such as the Supreme Court
decision in the lawsuit brought against us by the Association for
Molecular Pathology et al; risks of new, changing and competitive
technologies and regulations in the United States and
internationally; the risk that we may be unable to comply with
financial operating covenants under our credit or lending
agreements; the risk that we will be unable to pay, when due,
amounts due under our credit or lending agreements; and other
factors discussed under the heading "Risk Factors" contained in
Item 1A of our most recent Annual Report on Form 10-K for the
fiscal year ended June 30, 2019, which has been filed with the
Securities and Exchange Commission, as well as any updates to those
risk factors filed from time to time in our Quarterly Reports on
Form 10-Q or Current Reports on Form 8-K. All information in
this press release is as of the date of the release, and Myriad
undertakes no duty to update this information unless required by
law.
Media Contact: Ron
Rogers
Investor Contact: Scott
Gleason
(801) 584-3065
(801)
584-1143
rrogers@myriad.com
sgleason@myriad.com
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Sep 2023 to Sep 2024